| 1.06 0.114 (12.09%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.4 | 1-year : | 1.58 |
| Resists | First : | 1.2 | Second : | 1.36 |
| Pivot price | 1.07  |
|||
| Supports | First : | 0.94 | Second : | 0.78 |
| MAs | MA(5) : | 1.02 |
MA(20) : | 1.1 |
| MA(100) : | 1.37 |
MA(250) : | 2.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 10.8 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 7.53 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACXP ] has closed above bottom band by 42.3%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.07 - 1.08 | 1.08 - 1.08 |
| Low: | 1.01 - 1.01 | 1.01 - 1.02 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Tue, 03 Nov 2026
Acurx Pharmaceuticals, Inc. (ACXP) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
A majority is no longer the default: Acurx (ACXP) sets meeting quorum at one-third of voting power. - Stock Titan
Mon, 26 Oct 2026
Before markets open, Acurx will discuss its third-quarter results Nov. 12. - Stock Titan
Fri, 23 Oct 2026
Acurx Pharmaceuticals, Inc. Estimates – NASDAQ:ACXP - TradingView
Thu, 20 Aug 2026
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ... - Yahoo Finance
Fri, 14 Aug 2026
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 112 (K) |
| Shares Short P.Month | 121 (K) |
| EPS | -2.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56 % |
| Return on Equity (ttm) | -128.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|